Posted by Michael Wonder on 28 Feb 2024
Applied Therapeutics announces FDA acceptance and priority review of new drug application for govorestat for the treatment of classic galactosaemia
28 February 2024 - PDUFA target action date of 28 August 2024.
Applied Therapeutics today announced that the US FDA has accepted the filing of the new drug application for govorestat (AT-007) for the treatment of classic galactosaemia.
